Class Action Lawsuit Filed Against ImmunityBio Following FDA Warning and Stock Drop
A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) following an FDA warning letter and a significant drop in its stock price. The lawsuit alleges securities fraud and misleading promotions of the company's bladder-cancer drug, Anktiva. Investors who purchased shares during the class period are advised to contact Pomerantz LLP.
Tickers: $IBRX
Topics: class action FDA warning securities fraud stock price drop